WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.180.174'

Psyence Group Inc. PSYG.CN / PSYGF - Pot Stocks Charts, Financials, Analysts Price Targets, Insiders Transactions


Psyence Group Inc.

CNSX: PSYG


Canadian symbol: PSYG.CN
US symbol: PSYGF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 8.25M
Enterprise Value 8.43M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)46.78
Enterprise Value/Revenue 2.26k
Enterprise Value/EBITDA -1.32

Trading Information

Stock Price History

Beta (5Y Monthly) -0.38
52-Week Change 3-47.83%
S&P500 52-Week Change 312.18%
52 Week High 30.1800
52 Week Low 30.0000
50-Day Moving Average 30.0605
200-Day Moving Average 30.1060

Share Statistics

Avg Vol (3 month) 323.9k
Avg Vol (10 day) 330.42k
Shares Outstanding 5137.44M
Implied Shares Outstanding 6137.44M
Float 8131.28M
% Held by Insiders 14.05%
% Held by Institutions 10.00%
Shares Short (Sept 28, 2023) 41.97k
Short Ratio (Sept 28, 2023) 40.14
Short % of Float (Sept 28, 2023) 4N/A
Short % of Shares Outstanding (Sept 28, 2023) 40.00%
Shares Short (prior month Aug 30, 2023) 43.97k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Mar 30, 2023
Most Recent Quarter (mrq)Sept 29, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-178.32%
Return on Equity (ttm)-3,119.29%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -6.42M
Net Income Avi to Common (ttm)-6.62M
Diluted EPS (ttm)-0.0600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)856.5k
Total Cash Per Share (mrq)0.01
Total Debt (mrq)1.04M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.40
Book Value Per Share (mrq)-0.00

Cash Flow Statement

Operating Cash Flow (ttm)-5.43M
Levered Free Cash Flow (ttm)-2.91M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen



Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10



Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.


Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363




Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, bool given in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 460
Company News Date

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710


Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
Currency in CAD
Earnings EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. Estimate0000
Low Estimate0000
High Estimate0000
Year Ago EPSN/AN/AN/AN/A
Revenue EstimateCurrent Qtr.Next Qtr.Current YearNext Year
No. of Analysts0000
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings HistoryInvalid DateInvalid DateInvalid DateInvalid Date
EPS Est.N/AN/AN/AN/A
EPS ActualN/AN/AN/AN/A
DifferenceN/AN/AN/AN/A
Surprise %N/AN/AN/AN/A
EPS TrendCurrent Qtr.Next Qtr.Current YearNext Year
Current Estimate0000
7 Days Ago0000
30 Days Ago0000
60 Days Ago0000
90 Days Ago0000
EPS RevisionsCurrent Qtr.Next Qtr.Current YearNext Year
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPSYG.CNIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current YearN/AN/AN/AN/A
Next YearN/AN/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711


Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Currency in CAD
Breakdown
4.05%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Psyence Group Inc.


Psyence Group Announces SEC Effectiveness of F-4 for Proposed Business Combination Between Subsidiary and Nasdaq Listed Newcourt Acquisition Corp

TORONTO, Nov. 15, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC) (“Newcourt”), a special purpose acquisition company today announced that the registration stat... Read More...

Psyence Production Expands Capability

TORONTO, Oct. 30, 2023 -- Psyence Group Inc. (CSE:PSYG), a clinical-stage life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing (“Psyence”), is pleased to provide the following update on Psyence Production. Psyence Production is a division of Psyence that oversees its psilocybin ... Read More...

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

TORONTO, Aug. 21, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.... Read More...

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

VANCOUVER, British Columbia, Aug. 02, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) toda... Read More...

Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp

VANCOUVER, British Columbia, Jan. 09, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) formed for the purpose of acquir... Read More...

Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care

VANCOUVER, British Columbia, Dec. 15, 2022 -- Filament Health Corp. (OTCQB:FLHLF) (NEO:FH) (FSE:7QS) (“Filament”), a clinical-stage natural psychedelic drug development company, and Psyence Group Inc (CSE:PSYG | OTCQB: PSYGF) (“Psyence” and, together with Filament, the “Companies”), a life science biotechnology company pioneering the use ... Read More...

Psyence Group Announces Closing of Second Tranche of Private Placement and Appointment of Strategic Advisor

Psyence Group Inc.TORONTO, Dec. 14, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being is pleased to announce that it has closed the second tranche of its previously announced private placement o... Read More...

GOODMIND™ Available for Sale in the United Kingdom and Europe – Exclusive Distribution Agreement Concluded With This Works

TORONTO, Nov. 29, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that it has, together with its joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), ente... Read More...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...

Psyence Group Announces DTC Eligibility Approval in the U.S.

TORONTO, Feb. 09, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that the Company’s common shares are now eligible for electronic clearing and settlement through the D... Read More...

Psyence Awarded ISO Certification through the British Standards Institute for its Natural Psilocybin Production Facility

TORONTO, Feb. 07, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its ISO22000 graded Psilocybin production facility has officially received International Organiza... Read More...

Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6

TORONTO, Dec. 03, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that Psyence Chief Executive Officer, Neil Maresky, will be presenting at the virtual H.C. Wainwright ... Read More...

Psyence Group Announces Private Placement

TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible pro... Read More...

Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out in South Africa’s Largest Coffee Retail Chain

Company Broadens Revenue Generation InitiativesGOODMIND™Elevate your daily grind / GOODMIND™Elevate your daily grind / GOODMIND™TORONTO, Dec. 02, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-bein... Read More...

Psyence Group Inc. files Q2 Unaudited Condensed Consolidated Interim Financial Statements and MD&A

TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, announces that the Unaudited Condensed Consolidated Interim Financial Statements for the six months period ended September 30, 2021... Read More...

Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit

TORONTO, Nov. 26, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company with a focus on natural psychedelics in mental health and well-being, will break new ground as the first psychedelic company invited to speak at the 15th Annual Global Wellness Summit, a gathering of i... Read More...

Psyence Group Announces Commencement of Trading on OTCQB and DTC Eligibility of Common Shares in the United States Under the Ticker “PSYGF”

TORONTO, Oct. 13, 2021 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that, effective today, its common shares have been approved for trading on the OTCQB® Venture Market (... Read More...

Psyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts

A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extractsA leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Ex... Read More...

Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products

TORONTO and CAPE TOWN, South Africa, Aug. 18, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce the commencement of online sales and distribution of its premium range of functional mush... Read More...

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

TORONTO, July 07, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic C... Read More...

Psyence Group Corporate Update

TORONTO, May 27, 2021 -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.Psyence ProductionPsyence is federally licensed to cultivate and export psilo... Read More...

The Psyence Group Announces its Formal Entry into Jamaica with the Incorporation of its Wholly Owned Subsidiary, Psyence Jamaica Limited

TORONTO, June 08, 2021 -- Psyence Group Inc. (“Psyence” or the “Company”) (PSYG:CSE), a Canadian public biotechnology company with a global presence, is pleased to announce the incorporation, and operational commencement, of its wholly owned Jamaican subsidiary, “Psyence Jamaica Limited” (“Psyence Jamaica”).The Psyence Group has been oper... Read More...
Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Warning: file_get_contents(https://www.reuters.com/companies/PSYG.CD/listings): failed to open stream: HTTP request failed! HTTP/1.1 401 HTTP Forbidden in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 639
IndexLast% Change
S&P 5004,564.070.20%Positive
Euro STOXX 504,370.530.52%Positive
FTSE 1007,423.460.43%Negative
Nikkei 22533,321.220.26%Negative

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Warning: file_get_contents(https://www.reuters.com/companies/PSYG.CD/people): failed to open stream: HTTP request failed! HTTP/1.1 401 HTTP Forbidden in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 639
IndexLast% Change
S&P 5004,564.070.20%Positive
Euro STOXX 504,370.530.52%Positive
FTSE 1007,423.460.43%Negative
Nikkei 22533,321.220.26%Negative


Share this page